DBVT — DBV Technologies S.A.
—
Nasdaq ·
Health Care ·
Biotechnology ·
CIK 1613780 ·
France
Last close
$9.99
Market Cap
$627.78M
52W High
$26.18
52W Low
$8.63
ADV30
390,086
Next earnings
2026-10-28
Quarterly Fundamentals
Revenues vs Net Income (last 4 Q)
Assets vs Liabilities (last 4 Q)
| Period | Revenues | Gross profit | Op income | Net income | Assets | Cash | Liabilities |
|---|---|---|---|---|---|---|---|
| Sep 2026 | 0 | — | -64,800,000 | -64,500,000 | 215,400,000 | 165,700,000 | 66,800,000 |
| Jun 2026 | 0 | — | -50,600,000 | -50,400,000 | 223,200,000 | 174,900,000 | 62,800,000 |
| Mar 2026 | 0 | — | -47,900,000 | -47,600,000 | 266,400,000 | 229,200,000 | 58,500,000 |
| Dec 2025 | 0 | — | -45,048,000 | -44,829,000 | 233,718,000 | 194,167,000 | 64,948,000 |
Cashflow TTM (yfinance, fills SEC gap)
Operating CF
$-188,476,000
Investing CF
$-6,914,000
Financing CF
$296,060,000
CapEx
$-3,379,000
Dividends Paid
—
Buybacks
$-200,000
EPS Diluted TTM
$-3.05
As of
2026-11-01
Balance + Analyst (yfinance extras)
Retained Earnings
$-334,800,000
Inventory
—
Receivables
$17,500,000
ST Investments
—
EBIT TTM
$-208,348,000
Pretax Income TTM
$-206,255,000
Interest Exp TTM
—
Analysts
7
Yahoo Snapshot (yfinance, live)
Total Revenue
$3,762,000
EBITDA
$-205,476,000
Free Cash Flow
$-124,780,752
Enterprise Value
$438,509,952
Total Cash
$165,700,000
Total Debt
$7,500,000
Shares Out
62,840,707
Trailing EPS
$-3.00
Book Value
$2.37
ROE
-205.8%
ROA
-79.9%
Div Yield
0.00%
Annual Trend (SEC EDGAR, last 4y)
Revenues vs Net Income (last 4y)
| FY end | Revenues | Op income | Net income | Assets | Liabilities | Equity | Op cash flow |
|---|---|---|---|---|---|---|---|
| Dec 2025 | 0 | -147,054,000 | -146,947,000 | 233,718,000 | 64,948,000 | 168,770,000 | -121,181,000 |
| Dec 2024 | 0 | -116,590,000 | -113,918,000 | 65,658,000 | 38,271,000 | 27,388,000 | -104,474,000 |
| Dec 2023 | 0 | -76,433,000 | -72,726,000 | 182,986,000 | 42,799,000 | 140,186,000 | -79,653,000 |
| Dec 2022 | 0 | -96,631,000 | -96,274,000 | 246,518,000 | 52,065,000 | 194,454,000 | -55,666,000 |
TTM Snapshot
Revenues TTM
$5,018,000
NetIncome TTM
$-175,993,000
OpCashFlow TTM
—
Assets (Latest)
$223,200,000
Forward EPS
$-0.39
Max Pain — expiry 2027-05-21 (volume-derived — Yahoo OI feed degraded)
max pain strike: $10.00 · spot: $9.68 · call volume: 141 · put volume: 26
Expected Move to 2027-05-21:
±$4.83
(49.85%) —
implied range
$4.86 –
$14.51
· ATM straddle on $10.00 strike
Peers — same industry
| Ticker | Name | Market Cap | Last | Daily % |
|---|---|---|---|---|
| FDMT | 4D Molecular Therapeutics, Inc. | $608.33M | $10.79 | — |
| CGEM | Cullinan Therapeutics, Inc. | $602.14M | $9.27 | — |
| IAM | Iambic Therapeutics, Inc. | $674.04M | $14.22 | — |
| ATTO | Attovia Therapeutics, Inc. | $679.29M | $14.86 | — |
| SRZN | Surrozen, Inc./DE | $571.47M | $29.98 | — |
News headlines (Yahoo Finance, 1h cache)
DBV Technologies: 3 Key Takeaways for Long-Term Investors
2026-11-18 20:05 · Yahoo
DBV Technologies Highlights New Data from the VITESSE Phase 3 Study of the VIASKIN® Peanut Patch in Children Ages 4-7 Years
2026-11-12 15:00 · Yahoo
DBV Technologies Prepares Peanut Patch Launch as FDA Filing Decision Nears
2026-11-09 15:14 · Yahoo
DBV Technologies to Participate in Upcoming November Investor Conferences
2026-11-02 21:30 · Yahoo
DBV Technologies shares slide 8% on going-concern warning, wider Q3 loss
2026-10-29 09:15 · Yahoo
DBV Technologies (DBVT) Q3 2026 Earnings Call Transcript
2026-10-29 05:13 · Yahoo
What DBV Technologies (DBVT) Said on Its Q3 Earnings Call
2026-10-29 00:04 · Yahoo
DBV Technologies Reports Third Quarter 2026 Financial Results and Business Update
2026-10-28 20:47 · Yahoo
DBV Technologies to Report Third Quarter 2026 Financial Results and Business Update on October 28, 2026
2026-10-27 20:30 · Yahoo
European Equities Traded in the US as American Depositary Receipts Decline in Tuesday Trading
2026-10-27 15:13 · Yahoo
Recent Insider Activity
No insider activity indexed for this ticker.